Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vaxcyte, Inc.PCVX · Entity 1164 | SVP, GEN COUNSEL & CORP SEC | March 05, 2025 | March 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vaxcyte, Inc.
Report date March 05, 2025 · Filed March 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,620 |
Ending reported balance
After 2025-03-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-03-05 · Exercise / conversion · Acquired 5,000 · Balance 46,620 Row 2 · 2025-03-05 · Sale · Disposed 2,621 · Balance 43,999 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $69.745 to $70.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2025-03-05 · Sale · Disposed 2,267 · Balance 41,732 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $70.745 to $71.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2025-03-05 · Sale · Disposed 112 · Balance 41,620 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.41 · Expires 2032-05-08 | Direct | 144,497 |
Reported balance
After 2025-03-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-05 · Exercise / conversion · Disposed 5,000 · Balance 144,497 F4: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.
F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $69.745 to $70.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $70.745 to $71.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: 1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2023 Filed Dec 11, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 325 | $56.78 | $18,453.50 |
DisclosureSEC source: 0001209191-23-058061 · doc4.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,710 F3 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 10,000 | $56.50 | $565,000.00 |
DisclosureSEC source: 0001209191-23-058061 · doc4.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,035 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 21:36 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 10,000 | $21.41 | $214,100.00 |
DisclosureSEC source: 0001209191-23-058061 · doc4.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,035 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 548 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on November 17, 2023. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001209191-23-051898 · doc4.xml · derivative · entry 5 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 205,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,134 | $51.44 | $366,972.96 |
DisclosureSEC source: 0001209191-23-051898 · doc4.xml · nonDerivative · entry 4 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,487 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023. F4 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $50.97 to $51.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 4,874 | $50.22 | $244,772.28 |
DisclosureSEC source: 0001209191-23-051898 · doc4.xml · nonDerivative · entry 3 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,621 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023. F3 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $49.94 to $50.675. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | SaleCommon Stock | 7,992 | $49.58 | $396,243.36 |
DisclosureSEC source: 0001209191-23-051898 · doc4.xml · nonDerivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,495 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023. F2 · price: The price reported is a weighted-average price. The shares were sold at prices ranging from $48.94 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:07 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Exercise / conversionCommon Stock | 20,000 | $21.41 | $428,200.00 |
DisclosureSEC source: 0001209191-23-051898 · doc4.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 05, 2023 Filed Sep 6, 2023 21:35 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 1,189 | $51.00 | $60,639.00 |
DisclosureSEC source: 0001209191-23-048473 · doc4.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,487 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:24 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | Tax withholdingCommon Stock | 645 | $51.25 | $33,056.25 |
DisclosureSEC source: 0001209191-23-035854 · doc4.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,676 F1 · shares: Represents shares surrendered to the Issuer to cover applicable tax withholding obligations realized upon the vesting of restricted stock units. F2 · balance_after: Includes 539 shares acquired under the Vaxcyte, Inc. Employee Stock Purchase Plan on May 17, 2023. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $41.67 | $0.00 |
DisclosureSEC source: 0001209191-23-015724 · doc4.xml · derivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2033-03-01 F2 · derivative.exercise_date: 1/48 of shares subject to the option vest on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 22:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015724 · doc4.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,782 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on September 2, 2023 and 12.5% of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| December 30, 2022 Filed Jan 4, 2023 21:31 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 27,500 | $0.00 Strike: $47.95 | $0.00 |
DisclosureSEC source: 0001209191-23-000959 · doc4.xml · derivative · entry 2 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2032-12-30 F2 · derivative.exercise_date: 1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| June 07, 2022 Filed Jun 9, 2022 20:43 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035419 · doc4.xml · nonDerivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 25% of the shares subject to the award on June 7, 2023 and 12.5% of the shares every six months thereafter. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:11 UTC | Vaxcyte, Inc. PCVX · Entity 1164 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $21.41 | $0.00 |
DisclosureSEC source: 0001209191-22-028353 · doc4.xml · derivative · entry 1 Eydelman Mikhail · CIK 0001918033 · SVP, Gen Counsel & Corp Sec 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-05-08 F1 · derivative.exercise_date: 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.